Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineered zinc finger repressors induce a prolonged and selective repression of <i>SCN9A</i> in nociceptors of nonhuman primates.

Science translational medicine·2026
Same author

IL-2Rα is dispensable for murine B cell development and humoral response.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency.

Molecular therapy. Methods & clinical development·2024
Same author

Harnessing regulatory T cells to establish immune tolerance.

Science translational medicine·2024
Same author

Compact zinc finger architecture utilizing toxin-derived cytidine deaminases for highly efficient base editing in human cells.

Nature communications·2024
Same author

Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency.

Hepatology communications·2023
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Regeneration of the mammalian brain: a relic of evolution?

Stem cells (Dayton, Ohio)·2026
Same journal

Mitochondrial transfer technologies with molecular insights into clinical applications.

Stem cells (Dayton, Ohio)·2026
See all related articles

Related Experiment Video

Updated: May 30, 2025

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions
09:32

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Published on: November 11, 2015

11.9K

A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCs.

Helen Fong1,2, Matthew Mendel1, John Jascur1,2

  • 1Sangamo Therapeutics, Richmond, CA 94804, United States.

Stem Cells (Dayton, Ohio)
|January 29, 2025
PubMed
Summary
This summary is machine-generated.

This study presents a serum- and feeder-free method for large-scale production of induced pluripotent stem cell (iPSC)-derived CD4 T cells and regulatory T cells (Tregs). This scalable platform supports the development of cell therapies for oncology and autoimmune diseases.

More Related Videos

Small-scale Propagation of Human iPSCs in Serum-free Conditions for Routine Immunocytochemical Characterization
09:56

Small-scale Propagation of Human iPSCs in Serum-free Conditions for Routine Immunocytochemical Characterization

Published on: February 18, 2017

7.0K
Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System
09:16

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Published on: November 8, 2017

10.0K

Related Experiment Videos

Last Updated: May 30, 2025

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions
09:32

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Published on: November 11, 2015

11.9K
Small-scale Propagation of Human iPSCs in Serum-free Conditions for Routine Immunocytochemical Characterization
09:56

Small-scale Propagation of Human iPSCs in Serum-free Conditions for Routine Immunocytochemical Characterization

Published on: February 18, 2017

7.0K
Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System
09:16

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System

Published on: November 8, 2017

10.0K

Area of Science:

  • Stem Cell Biology
  • Immunology
  • Cell Therapy

Background:

  • Induced pluripotent stem cells (iPSCs) offer a renewable source for cell manufacturing, overcoming primary cell limitations.
  • Existing methods for clinical-grade iPSC-derived CD4 T cells and regulatory T cells (Tregs) often require animal components or complex organoid systems.
  • Scalable production of iPSC-derived T cells is crucial for advancing cell-based therapies.

Purpose of the Study:

  • To develop a serum- and feeder-free differentiation process for large-scale manufacturing of iPSC-derived CD4 T cells and Tregs.
  • To demonstrate the efficient generation and functional characterization of iPSC-derived Tregs, including those engineered with a CAR.
  • To establish a versatile iPSC platform for producing both CD4 T cells and Tregs for therapeutic applications.

Main Methods:

  • Optimized differentiation of iPSCs into CD4 T cells using specific concentrations of PMA/Ionomycin.
  • Conversion of iPSC-derived CD4 T cells into Tregs using TGFβ and ATRA.
  • Non-viral, targeted genetic engineering of iPSCs for CAR integration (e.g., HLA-A2 CAR).
  • Phenotypic, transcriptional, and functional analysis of engineered iPSC-Tregs compared to primary Tregs.

Main Results:

  • High-efficiency generation of iPSC-derived CD4 T cells and subsequent conversion to Tregs.
  • Successful non-viral, targeted integration of an HLA-A2 CAR into iPSCs.
  • iPSC-Tregs (with or without CAR) demonstrated phenotypic, transcriptional, and functional similarity to primary Tregs.
  • In vitro suppression of T-cell proliferation by iPSC-Tregs was confirmed.

Conclusions:

  • A scalable, serum- and feeder-free platform for manufacturing iPSC-derived CD4 T cells and Tregs has been established.
  • This platform enables the production of functional iPSC-Tregs, suitable for Treg cell therapies.
  • The technology complements existing iPSC-CD8 oncology products and offers a pathway for large-scale Treg cell therapy manufacturing.